JenKem Technology, established in 2001 in Tianjin and listed on the Shanghai Stock Exchange STAR Market since 2020 (688356.SH), develops and manufactures high-purity, low-polydispersity PEG and PEG co-polymer derivatives in batch sizes from 1 gram to over 40 kilograms under ISO9001 and ISO13485-certified quality systems following ICH Q7 GMP guidelines, alongside controlled manufacture of raw polyethylene glycol polymers with more than 10 metric tons of annual capacity. The company holds 86 approved patents (as of 2021) with 43 further pending, has filed multiple US and China DMFs for its PEG products, and operates a dedicated Innovation Research Institute (established 2019) supporting continued PEGylation technology development. Manufacturing active pharmaceutical ingredients and finished dosage forms, the company offers CRO and CDMO services to markets across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa, trading on brand strength, international certification, and an experienced R&D team.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen